Table 3.

Univariate Cox regression analysis of local recurrence rate in patients with rectal cancer

	HR	95% CI	P value
Pathological tumor size < 5cm (RG: ≥5 cm)	0.18	0.06-0.58	0.004
CRM negative (RG: CRM positive)	0.20	0.05-0.82	0.025
WD adenocarcinoma (RG: PD adenocarcinoma)	0.03	0.03-0.38	0.006
MD adenocarcinoma (RG: PD adenocarcinoma)	0.05	0.01-0.41	0.005
LVI negative (RG: LVI positive)	0.40	0.14-1.17	0.094
LAR (RG: APR)	0.01	0.04-0.23	0.001
Pathological T1-3 (RG: pathological T4)	0.18	0.05-0.64	0.008
Pathological N0 (RG: pathological N1-2)	1.02	0.36-2.86	0.975
No adjuvant RT (RG: adjuvant RT)	0.25	0.09-0.70	0.008
No adjuvant CT (RG: adjuvant CT)	0.64	0.22-1.79	0.394
No neoadjuvant CCRT (RG: neoadjuvant CCRT)	0.62	0.17-2.20	0.458
Age ≤ 65 years (RG: >65 years)	1.07	0.39-2.96	0.892
Men (RG: Women)	0.83	0.30-2.30	0.712
Upper- and middle-third rectum (RG: lower-third rectum)	0.18	0.06-0.54	0.002

HR, hazard ratio; CI, confidence interval; RG, reference group; RT, radiotherapy; CT, chemotherapy; APR, abdominal perineal resection; LAR, lower anterior resection; CRM: circumferential margin; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; LVI, lymphatic vascular invasion; CCRT, concurrent chemoradiotherapy